9926:HKG
Akeso Inc
HK$91.30
arrow_upward
+0.94%(+0.85) 1D
Okt 16, 4:08:14 PM GMT+8 · HKD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa 9926...
Buksan
HK$92.15
Mataas
HK$95.30
Mababa
HK$90.15
Mkt. cap
84.10B
Avg. na dami
10.45M
Dami
11.09M
Mataas nang 52-wk
HK$156.00
Mababa nang 52-wk
HK$80.20
EPS
-HK$1.24
Bilang ng mga empleyado
4K
Buksan
HK$92.15
Mataas
HK$95.30
Mababa
HK$90.15
Mkt. cap
84.10B
Avg. na dami
10.45M
Dami
11.09M
Mataas nang 52-wk
HK$156.00
Mababa nang 52-wk
HK$80.20
EPS
-HK$1.24
Bilang ng mga empleyado
4K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Simply Wall Street
·
4 oras ang nakalipas
Is Akeso (SEHK:9926) Undervalued On Its Phase III Colon Cancer Trial News?
Yahoo Finance
·
1 araw ang nakalipas
Will Phase III Colon Cancer Trial Change Akeso Stock Narrative
Profile
Akeso, Inc is a publicly listed Chinese biopharmaceutical company that is headquartered in Zhongshan, Guangdong.
It is best known for developing Ivonescimab, a cancer treatment antibody. Wikipedia
Tungkol sa Akeso Inc
CEOMichelle Xia | Michelle Xia
Mga Empleyado4.08K
ItinatagMar 19, 2012
Headquarters-
Sektor-
Websiteakesobio.com